 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Acute Pharmacological Effects of Oral and Intranasal Mephedrone : |
(Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) (Universitat Pompeu Fabra) (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) (Associació Benestar i Desenvolupament) (Institut Hospital del Mar d'Investigacions Mèdiques) (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
| Data: | 2021 |
| Resum: | Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic conditions. An observational study was conducted to assess and compare the acute pharmacological effects, as well as the oral fluid (saliva) concentrations of mephedrone self-administered orally and intranasally. Ten healthy experienced drug users (4 females and 6 males) self-administered a single dose of mephedrone, orally (n = 5, 100-200 mg; mean 150 mg) or intranasally (n = 5, 50-100 mg, mean 70 mg). Vital signs (blood pressure, heart rate, and cutaneous temperature) were measured at baseline (0), 1, 2, and 4 h after self-administration. Each participant completed subjective effects questionnaires: A set of Visual Analogue Scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI), and Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 1, 2, and 4 h after self-administration. Oral fluid and urine were collected during 4 h. Both routes of mephedrone self-administration enhanced ratings of euphoria and well-being effects and increased cardiovascular effects in humans. Although it was at times assessed that the oral route produced greater and larger effects than the intranasal one, concentrations of mephedrone in oral fluid and also the total amount of mephedrone and metabolites in urine showed of mephedrone are considerably higher when self-administered intranasally in comparison to orally. Controlled clinical trials are needed to confirm our observational results. |
| Ajuts: | Instituto de Salud Carlos III FIS PI14/00715 Instituto de Salud Carlos III FIS PI17/01962 Instituto de Salud Carlos III RD16/0017/0003 Instituto de Salud Carlos III RD16/0017/0010 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017 SGR 316 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017 SGR 530 European Commission HOME/2014/JDRU/AG/DRUG/7082 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Mephedrone (4-methylmethcathinone) ; Novel psychoactive substances (NPS) ; Psychostimulants ; Cathinones bath salts ; Oral administration ; Intranasal administration |
| Publicat a: | Pharmaceuticals, Vol. 14 Núm. 2 (2021) , p. 100, ISSN 1424-8247 |
